Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Replidyne, Inc.
WARNING LETTER
•Replidyne, Inc.•October 17, 2006

Replidyne, Inc. – FDA Warning Letter, Oct 17, 2006

Record Details

This Warning Letter, dated January 18, 2008, informs Replidyne, Inc. of objectionable conditions found during FDA investigations between July 2006 and October 2006, concerning their role as the applicant for NDA [redacted] for the drug [redacted]. The FDA's Bioresearch Monitoring Program aims to ensure research conduct, human subject protection, and data validity.

Replidyne acquired rights to clinical investigations sponsored by [redacted] (conducted 2000-2003) and submitted a marketing application on December 20, 2005. The FDA identified two key deficiencies:

1. **Failure to make underlying raw data available for FDA audit [21 CFR 314.3(b)]**: Replidyne failed to provide all raw data. Examples include inability to obtain SOPs from [redacted], missing monitoring visit reports for Protocol [redacted] Clinical Site #36, and inability to locate or access records for two international clinical investigators (Dr. [redacted] and Dr. [redacted]). The FDA emphasized Replidyne's responsibility, as the applicant, to ensure all underlying raw data was available prior to submission.

2. **Failure to provide adequate descriptions and analyses of relevant safety and effectiveness data [21 CFR 314.50(d)(5)(iv)]**: Replidyne submitted

Company
Replidyne, Inc.
Inspection date
October 17, 2006
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • Leslie K. Ball
View Company Profile

ID · 51defbf4-f649-4c7d-ad9c-1914af8bbc2e

Violation Codes3
21 CFR 314.3(b)21 CFR 314.50(d)(5)(iv)21 CFR 312.62(c)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Replidyne, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.